CA1092601A - Derivatives of somatostatin - Google Patents
Derivatives of somatostatinInfo
- Publication number
- CA1092601A CA1092601A CA247,515A CA247515A CA1092601A CA 1092601 A CA1092601 A CA 1092601A CA 247515 A CA247515 A CA 247515A CA 1092601 A CA1092601 A CA 1092601A
- Authority
- CA
- Canada
- Prior art keywords
- phe
- cys
- gly
- ala
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 11
- -1 hydroxy, amino Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000002596 lactones Chemical group 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 12
- 150000003254 radicals Chemical class 0.000 claims 6
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 abstract description 4
- 108010051696 Growth Hormone Proteins 0.000 abstract description 4
- 239000000122 growth hormone Substances 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 3
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- KNPVDQMEHSCAGX-UWVGGRQHSA-N Phe-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KNPVDQMEHSCAGX-UWVGGRQHSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000003839 salts Chemical group 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- JPNRPAJITHRXRH-BQBZGAKWSA-N Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O JPNRPAJITHRXRH-BQBZGAKWSA-N 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- QCZJFMXMDLPIAN-VKHMYHEASA-N (3s)-3-amino-4-hydroxybutanamide Chemical compound OC[C@@H](N)CC(N)=O QCZJFMXMDLPIAN-VKHMYHEASA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- XAGIMRPOEJSYER-CIUDSAMLSA-N Ala-Cys-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XAGIMRPOEJSYER-CIUDSAMLSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- TWXZVVXRRRRSLT-IMJSIDKUSA-N Asn-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O TWXZVVXRRRRSLT-IMJSIDKUSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- LHMSYHSAAJOEBL-CIUDSAMLSA-N Cys-Lys-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O LHMSYHSAAJOEBL-CIUDSAMLSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N L-cysteine hydrochloride hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- WPSXZFTVLIAPCN-WDSKDSINSA-N Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O WPSXZFTVLIAPCN-WDSKDSINSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CWBHKBKGKCDGDM-UHFFFAOYSA-N bis[(2,2,2-trifluoroacetyl)oxy]boranyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OB(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F CWBHKBKGKCDGDM-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229940068004 oxypolygelatine Drugs 0.000 description 1
- 108010014241 oxypolygelatine Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH305575 | 1975-03-11 | ||
CH3055/75 | 1975-03-11 | ||
CH357275 | 1975-03-20 | ||
CH3572/75 | 1975-03-20 | ||
CH1061075 | 1975-08-14 | ||
CH10610/75 | 1975-08-14 | ||
CH1228275 | 1975-09-22 | ||
CH12282/75 | 1975-09-22 | ||
CH12586/75 | 1975-09-29 | ||
CH1258675 | 1975-09-29 | ||
CH1511775 | 1975-11-21 | ||
CH1511975 | 1975-11-21 | ||
CH15119/75 | 1975-11-21 | ||
CH15118/75 | 1975-11-21 | ||
CH1511875 | 1975-11-21 | ||
CH15117/75 | 1975-11-21 | ||
CH1525275 | 1975-11-25 | ||
CH15252/75 | 1975-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1092601A true CA1092601A (en) | 1980-12-30 |
Family
ID=27575775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA247,515A Expired CA1092601A (en) | 1975-03-11 | 1976-03-10 | Derivatives of somatostatin |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPS51115467A (en, 2012) |
AU (1) | AU509661B2 (en, 2012) |
CA (1) | CA1092601A (en, 2012) |
DE (1) | DE2608336A1 (en, 2012) |
FI (1) | FI760539A7 (en, 2012) |
FR (1) | FR2303560A1 (en, 2012) |
GB (1) | GB1546517A (en, 2012) |
IE (1) | IE44284B1 (en, 2012) |
IL (1) | IL49180A (en, 2012) |
NL (1) | NL7602395A (en, 2012) |
NO (1) | NO760707L (en, 2012) |
NZ (1) | NZ180247A (en, 2012) |
PT (1) | PT64881B (en, 2012) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4104267A (en) * | 1977-02-22 | 1978-08-01 | American Home Products Corporation | Somatostatin analogs |
GB1596329A (en) * | 1977-04-21 | 1981-08-26 | Lilly Co Eli | Tetradeca peptides |
US4100117A (en) * | 1977-04-21 | 1978-07-11 | Eli Lilly And Company | Somatostatin analogs and intermediates thereto |
US4118380A (en) * | 1977-07-25 | 1978-10-03 | Ayerst, Mckenna & Harrison Limited | Decapeptide analogs of somatostatin |
US4244947A (en) * | 1979-08-13 | 1981-01-13 | Ayerst Mckenna And Harrison Inc. | Carba decapeptide derivatives of [TYR6 ]-somatostatin |
DK81082A (da) * | 1981-03-06 | 1982-09-07 | Sandoz Ag | Fremgangsmaade til fremstilling af polypeptider |
JPS57183797A (en) * | 1981-05-06 | 1982-11-12 | Yamanouchi Pharmaceut Co Ltd | Straight and purely short-chain peptide and its preparation |
EP0084540A4 (en) * | 1981-07-17 | 1985-04-24 | John Trevor Rice | MOTOR-PUMP ASSEMBLY. |
US4485101A (en) * | 1983-10-11 | 1984-11-27 | Administrators Of The Tulane Educational Fund | Peptides |
WO2008147765A1 (en) | 2007-05-22 | 2008-12-04 | Wyeth | Improved processes for making hydrazides |
ES2711363T3 (es) * | 2012-04-16 | 2019-05-03 | Allergan Inc | Derivados de (2-ureidoacetamido)alquilo como moduladores del receptor 2 de péptidos formilados |
-
1976
- 1976-03-01 DE DE19762608336 patent/DE2608336A1/de not_active Withdrawn
- 1976-03-02 FI FI760539A patent/FI760539A7/fi not_active Application Discontinuation
- 1976-03-03 NO NO760707A patent/NO760707L/no unknown
- 1976-03-08 NL NL7602395A patent/NL7602395A/xx not_active Application Discontinuation
- 1976-03-09 GB GB9313/76A patent/GB1546517A/en not_active Expired
- 1976-03-09 IL IL49180A patent/IL49180A/xx unknown
- 1976-03-09 NZ NZ180247A patent/NZ180247A/xx unknown
- 1976-03-09 IE IE493/76A patent/IE44284B1/en unknown
- 1976-03-09 PT PT64881A patent/PT64881B/pt unknown
- 1976-03-10 FR FR7606828A patent/FR2303560A1/fr active Granted
- 1976-03-10 CA CA247,515A patent/CA1092601A/en not_active Expired
- 1976-03-10 JP JP51025198A patent/JPS51115467A/ja active Pending
- 1976-03-11 AU AU11893/76A patent/AU509661B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
IE44284L (en) | 1976-09-11 |
PT64881B (fr) | 1977-11-17 |
IL49180A (en) | 1980-12-31 |
IE44284B1 (en) | 1981-10-07 |
NZ180247A (en) | 1978-09-25 |
GB1546517A (en) | 1979-05-23 |
IL49180A0 (en) | 1976-05-31 |
FI760539A7 (en, 2012) | 1976-09-12 |
NO760707L (en, 2012) | 1976-09-14 |
FR2303560B1 (en, 2012) | 1978-11-17 |
FR2303560A1 (fr) | 1976-10-08 |
JPS51115467A (en) | 1976-10-12 |
DE2608336A1 (de) | 1976-09-30 |
PT64881A (fr) | 1976-04-01 |
AU509661B2 (en) | 1980-05-22 |
NL7602395A (nl) | 1976-09-14 |
AU1189376A (en) | 1977-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4291022A (en) | Organic compounds | |
CA1148146A (en) | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture | |
US4603120A (en) | Cyclic octapeptides and pharmaceutical preparations thereof, as well as processes for their manufacture, and their use | |
CA1092601A (en) | Derivatives of somatostatin | |
US4261886A (en) | Peptides having thymopoietin-like activity | |
JP2514518B2 (ja) | ヘプタペプチドおよびオクタペプチドのソマトスタチン類似アミド誘導体、それを含有する抗腫瘍剤 | |
CA1236451A (en) | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | |
US4707468A (en) | Polypeptide | |
JPS61293997A (ja) | 生活性リジン含有オクタペプチド及びその調整方法 | |
EP0187622A2 (en) | Somatostatin derivatives | |
EP2473518B1 (en) | Stabilized melanocortin ligands | |
JPS59500863A (ja) | ゴナドリベリン誘導体、その製造方法及びその医薬及び獣医薬組成物 | |
PL169498B1 (pl) | Sposób wytwarzania nowych zwiazków polipeptydowych PL PL | |
US3853836A (en) | Psychopharmacologically active peptides related to acth | |
US3842064A (en) | Psychopharmacologically active tetra-,penta-,hexa-,and hepta-peptides | |
CA1105006A (en) | Peptides | |
JPH02500517A (ja) | ペプチド化合物 | |
JPH04500666A (ja) | ペプチド化合物 | |
CA1066695A (en) | Cyclic undecapeptide analogs of somatostatin and intermediates | |
US4110322A (en) | Peptide derivatives and pharmaceutical compositions containing same | |
US3856770A (en) | Psychopharmacologically active tetra-, penta-, hexa-, and heptapeptides | |
US3770715A (en) | Acth active peptides having d serine as first aminoacid from n terminus and l ornithine as11 aminoacid | |
US4203975A (en) | Psychopharmacological peptides suitable for therapeutic administration | |
HU185229B (en) | Process for preparing pharmaceutically active peptides and acetates thereof | |
US4496543A (en) | Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |